Skip to content

Zymeworks ZYME Total costs & expenses

Total costs & expenses at other companies

TG Therapeutics logo
TG TherapeuticsTGTX
$170.12M+51.6%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$34.35M-57.9%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$90.08M+9.8%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$858.01M+590%
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's total costs & expenses?
Zymeworks (ZYME) reported total costs & expenses of $49.53M in Q1 2026.
How has Zymeworks's total costs & expenses changed year-over-year?
Zymeworks's total costs & expenses decreased by 6.1% year-over-year, from $52.72M to $49.53M.
What is the long-term trend for Zymeworks's total costs & expenses?
Over 3 years (2022 to 2025), Zymeworks's total costs & expenses has grown at a -11.0% compound annual growth rate (CAGR), from $281.95M to $198.51M.
What does total costs & expenses mean?
The aggregate sum of all operating and non-operating costs incurred by the company during the reporting period, including research, development, and administrative overhead. Monitoring this metric is essential for assessing the company's burn rate and overall operational efficiency.